REGADENOSON
| Brand name | LEXISCAN |
|---|---|
| Active ingredient | REGADENOSON |
| Strength | 0.4MG/5ML (0.08MG/ML) |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | April 2008 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 8106183 | February 2027 | substance |
| RE47301 | February 2027 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.